This Article Full Text Full Text (PDF) All Versions of this Article: 200707-1083OCv1 177/8/896    most recent Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zaiman, A. L. Articles by Tuder, R. M. Search for Related Content PubMed PubMed Citation Articles by Zaiman, A. L. Articles by Tuder, R. M.

Role of the TGF-β/Alk5 Signaling Pathway in Monocrotaline-induced Pulmonary Hypertension

¹ Division of Pulmonary and Critical Care Medicine, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland; ² Scios, Inc., Fremont, California; ³ Department Cell Biology and Anatomy, New York Medical College, Valhalla, New York; and ⁴ Division of Cardiopulmonary Pathology, Department of Pathology, and ⁵ Division of Cardiology, Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland

Correspondence and requests for reprints should be addressed to Ari L. Zaiman, M.D., Ph.D., Johns Hopkins School of Medicine, Division of Pulmonary and Critical Care Medicine, 1830 East Monument Street, 5th Floor, Baltimore, MD 21205. E-mail: azaiman1{at}jhmi.edu

Rationale: Pulmonary arterial hypertension is a progressive disease characterized by an elevation in the mean pulmonary artery pressure leading to right heart failure and a significant risk of death. Alterations in two transforming growth factor (TGF) signaling pathways, bone morphogenetic protein receptor II and the TGF-β receptor I, Alk1, have been implicated in the pathogenesis of pulmonary hypertension (PH). However, the role of TGF-β family signaling in PH and pulmonary vascular remodeling remains unclear.

Objectives: To determine whether inhibition of TGF-β signaling will attenuate and reverse monocrotaline-induced PH (MCT-PH).

Methods: We have used an orally active small-molecule TGF-β receptor I inhibitor, SD-208, to determine the functional role of this pathway in MCT-PH.

Measurements and Main Results: The development of MCT-PH was associated with increased vascular cell apoptosis, which paralleled TGF-β signaling as documented by psmad2 expression. Inhibition of TGF-β signaling with SD-208 significantly attenuated the development of the PH and reduced pulmonary vascular remodeling. These effects were associated with decreased early vascular cell apoptosis, adventitial cell proliferation, and matrix metalloproteinase expression. Inhibition of TGF-β signaling with SD-208 in established MCT-PH resulted in a small but significant improvement in hemodynamic parameters and medial remodeling.

Conclusions: These findings provide evidence that increased TGF-β signaling participates in the pathogenesis of experimental severe PH.

Key Words: pulmonary hypertension • transforming growth factor-β • apoptosis • proliferation • matrix metalloproteinase

AT A GLANCE COMMENTARY Scientific Knowledge on the Subject Transforming growth factor (TGF)-β signaling pathways have been implicated in the pathogenesis of pulmonary hypertension (PH); however, the mechanism by which altered signaling leads to PH is unknown. To understand its role, animal models have been used, but the level of TGF-β varies. What This Study Adds to the Field Increased TGF-β signaling participates in the pathogenesis of experimental severe PH.

 

This article has been cited by other articles:

				C. S. Thompson-Torgerson, H. C. Champion, L. Santhanam, Z. L. Harris, and A. A. Shoukas Cyclohexanone contamination from extracorporeal circuits impairs cardiovascular function Am J Physiol Heart Circ Physiol, June 1, 2009; 296(6): H1926 - H1932. [Abstract] [Full Text] [PDF]

				Q. Lu, B. Patel, E. O. Harrington, and S. Rounds Transforming growth factor-{beta}1 causes pulmonary microvascular endothelial cell apoptosis via ALK5 Am J Physiol Lung Cell Mol Physiol, May 1, 2009; 296(5): L825 - L838. [Abstract] [Full Text] [PDF]

				D. J. Angelini, Q. Su, K. Yamaji-Kegan, C. Fan, J. T. Skinner, H. C. Champion, M. T. Crow, and R. A. Johns Hypoxia-induced mitogenic factor (HIMF/FIZZ1/RELM{alpha}) induces the vascular and hemodynamic changes of pulmonary hypertension Am J Physiol Lung Cell Mol Physiol, April 1, 2009; 296(4): L582 - L593. [Abstract] [Full Text] [PDF]

				L. Long, A. Crosby, X. Yang, M. Southwood, P. D. Upton, D.-K. Kim, and N. W. Morrell Altered Bone Morphogenetic Protein and Transforming Growth Factor-{beta} Signaling in Rat Models of Pulmonary Hypertension: Potential for Activin Receptor-Like Kinase-5 Inhibition in Prevention and Progression of Disease Circulation, February 3, 2009; 119(4): 566 - 576. [Abstract] [Full Text] [PDF]

				M. Thomas, C. Docx, A. M. Holmes, S. Beach, N. Duggan, K. England, C. Leblanc, C. Lebret, F. Schindler, F. Raza, et al. Activin-Like Kinase 5 (ALK5) Mediates Abnormal Proliferation of Vascular Smooth Muscle Cells from Patients with Familial Pulmonary Arterial Hypertension and Is Involved in the Progression of Experimental Pulmonary Arterial Hypertension Induced by Monocrotaline Am. J. Pathol., February 1, 2009; 174(2): 380 - 389. [Abstract] [Full Text] [PDF]

				R. J. Davies and N. W. Morrell Molecular Mechanisms of Pulmonary Arterial Hypertension: Role of Mutations in the Bone Morphogenetic Protein Type II Receptor Chest, December 1, 2008; 134(6): 1271 - 1277. [Abstract] [Full Text] [PDF]

				L. J. Ellmers, N. J. A. Scott, S. Medicherla, A. P. Pilbrow, P. G. Bridgman, T. G. Yandle, A. M. Richards, A. A. Protter, and V. A. Cameron Transforming Growth Factor-{beta} Blockade Down-Regulates the Renin-Angiotensin System and Modifies Cardiac Remodeling after Myocardial Infarction Endocrinology, November 1, 2008; 149(11): 5828 - 5834. [Abstract] [Full Text] [PDF]

				Q. Lu Transforming growth factor-{beta}1 protects against pulmonary artery endothelial cell apoptosis via ALK5 Am J Physiol Lung Cell Mol Physiol, July 1, 2008; 295(1): L123 - L133. [Abstract] [Full Text] [PDF]